全球氣喘生物製藥市場規模、佔有率、趨勢和成長分析報告（2026-2034）

預計氣喘生物製劑市場將從 2025 年的 99.5 億美元成長到 2034 年的 293.1 億美元，2026 年至 2034 年的複合年成長率為 12.76%。

由於重症和難治性氣喘病例數量不斷增加，全球氣喘生物製劑市場正經歷強勁成長。生物製劑療法可針對特定的免疫通路，為對傳統療法無反應的患者提供更佳的治療效果。人們對先進氣喘管理的認知不斷提高，以及獲得專業醫療服務的途徑日益便捷，都推動了市場擴張。

關鍵成長要素包括單株抗體療法的進步和臨床研究投入的增加。製藥公司正致力於採用個人化醫療方法來提高治療效果。已開發地區醫療保健支出的增加和有利的報銷機制正在推動該療法的普及。此外，診斷技術的進步，尤其是用於識別合格患者的技術，也增強了市場需求。

鑑於對新型生物標的和聯合治療的持續研究，前景十分樂觀。新興市場不斷完善的醫療基礎設施將為市場開闢新的成長途徑。各公司正加大對病患支持計畫和創新給藥方法的投入。隨著精準醫療的不斷發展，全球氣喘生物製藥市場預計將實現持續的長期成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球氣喘生物製藥市場：依藥物類別分類

• 市場分析、洞察與預測
• 選擇性免疫抑制劑
• 白細胞介素抑制劑
• 其他

第5章 全球氣喘生物製藥市場：依通路分類

• 市場分析、洞察與預測
• 零售藥房
• 電子商務
• 其他

第6章 全球氣喘生物製藥市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第7章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第8章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Amgen Inc
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd
  • GSK Plc
  • Novartis AG
  • Regeneron Pharmaceuticals Inc
  • Sanofi
  • Teva Pharmaceutical Industries Ltd
  • GlaxoSmithKline
  • AstraZeneca Plc

The Asthma Biologics Market size is expected to reach USD 29.31 Billion in 2034 from USD 9.95 Billion (2025) growing at a CAGR of 12.76% during 2026-2034.

The Global Asthma Biologics Market is experiencing robust growth due to increasing prevalence of severe and uncontrolled asthma cases. Biologic therapies target specific immune pathways, offering improved outcomes for patients who do not respond to traditional treatments. Rising awareness about advanced asthma management and improved access to specialty care are supporting market expansion.

Major growth drivers include advancements in monoclonal antibody therapies and growing clinical research investments. Pharmaceutical companies are focusing on personalized medicine approaches to enhance treatment effectiveness. Increasing healthcare spending and supportive reimbursement frameworks in developed regions are boosting adoption. Additionally, improved diagnostic techniques for identifying eligible patients are strengthening demand.

Future prospects appear promising as ongoing research explores new biologic targets and combination therapies. Emerging markets with expanding healthcare infrastructure will create new growth avenues. Companies are investing in patient support programs and innovative delivery methods. As precision medicine continues to evolve, the Global Asthma Biologics Market is expected to witness sustained long-term expansion.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• Selective Immuno-suppressants
• Interleukin Inhibitors
• Others

By Distribution Channel

• Retail Pharmacies
• E-commerce
• Others

COMPANIES PROFILED

• Amgen Inc, AstraZeneca, F HoffmannLa Roche Ltd, GSK plc, Novartis AG, Regeneron Pharmaceuticals Inc, Sanofi, Teva Pharmaceutical Industries Ltd, GlaxoSmithKline, AstraZeneca plc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ASTHMA BIOLOGICS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Selective Immuno-suppressants Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Interleukin Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ASTHMA BIOLOGICS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Distribution Channel
• 5.2. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. E-commerce Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ASTHMA BIOLOGICS MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Drug Class
  • 6.2.2 By Distribution Channel
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Drug Class
  • 6.3.2 By Distribution Channel
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Drug Class
  • 6.4.2 By Distribution Channel
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Drug Class
  • 6.5.2 By Distribution Channel
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Drug Class
  • 6.6.2 By Distribution Channel
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL ASTHMA BIOLOGICS INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Amgen Inc
  • 8.2.2 AstraZeneca
  • 8.2.3 F. Hoffmann-La Roche Ltd
  • 8.2.4 GSK Plc
  • 8.2.5 Novartis AG
  • 8.2.6 Regeneron Pharmaceuticals Inc
  • 8.2.7 Sanofi
  • 8.2.8 Teva Pharmaceutical Industries Ltd
  • 8.2.9 GlaxoSmithKline
  • 8.2.10 AstraZeneca Plc